Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome

NCT04900350 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT04900350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04900350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome
Lead sponsor
Akeso
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 18, 2021
Completion date
December 31, 2025
Enrollment
136 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome